Acute or delayed systemic administration of human amnion epithelial cells improves outcomes in experimental stroke

Evans, MA; Lim, R; Kim, HA; Chu, HX; Gardiner-Mann, CV; Taylor, KWE; Chan, CT; Brait, VH; Lee, S; Dinh, QN; Vinh, A; Phan, TG; Srikanth, VK; Ma, H; Arumugam, TV; Fann, DY; Poh, L; Hunt, CPJ; Pouton, CW; Haynes, JM; Selemidis, S; Kwan, W; Teo, L; Bourne, JA; Neumann, S; Young, S; Gowing, EK; Drummond, GR; Clarkson, AN; Wallace, EM; Sobey, CG; Broughton, BRS

eCite Digital Repository

Acute or delayed systemic administration of human amnion epithelial cells improves outcomes in experimental stroke

Citation

Evans, MA and Lim, R and Kim, HA and Chu, HX and Gardiner-Mann, CV and Taylor, KWE and Chan, CT and Brait, VH and Lee, S and Dinh, QN and Vinh, A and Phan, TG and Srikanth, VK and Ma, H and Arumugam, TV and Fann, DY and Poh, L and Hunt, CPJ and Pouton, CW and Haynes, JM and Selemidis, S and Kwan, W and Teo, L and Bourne, JA and Neumann, S and Young, S and Gowing, EK and Drummond, GR and Clarkson, AN and Wallace, EM and Sobey, CG and Broughton, BRS, Acute or delayed systemic administration of human amnion epithelial cells improves outcomes in experimental stroke, Stroke, 49, (3) pp. 700-709. ISSN 0039-2499 (2018) [Refereed Article]

Copyright Statement

DOI: doi:10.1161/STROKEAHA.117.019136

Abstract

Background and Purpose: Human amnion epithelial cells (hAECs) are nonimmunogenic, nontumorigenic, anti-inflammatory cells normally discarded with placental tissue. We reasoned that their profile of biological features, wide availability, and the lack of ethical barriers to their use could make these cells useful as a therapy in ischemic stroke.

Methods: We tested the efficacy of acute (1.5 hours) or delayed (1-3 days) poststroke intravenous injection of hAECs in 4 established animal models of cerebral ischemia. Animals included young (7-14 weeks) and aged mice (20-22 months) of both sexes, as well as adult marmosets of either sex.

Results: We found that hAECs administered 1.5 hours after stroke in mice migrated to the ischemic brain via a CXC chemokine receptor type 4-dependent mechanism and reduced brain inflammation, infarct development, and functional deficits. Furthermore, if hAECs administration was delayed until 1 or 3 days poststroke, long-term functional recovery was still augmented in young and aged mice of both sexes. We also showed proof-of-principle evidence in marmosets that acute intravenous injection of hAECs prevented infarct development from day 1 to day 10 after stroke.

Conclusions: Systemic poststroke administration of hAECs elicits marked neuroprotection and facilitates mechanisms of repair and recovery.

Item Details

Item Type:	Refereed Article
Keywords:	brain ischemia, cerebral infarction, inflammation, mice, stem cells
Research Division:	Biomedical and Clinical Sciences
Research Group:	Cardiovascular medicine and haematology
Research Field:	Cardiology (incl. cardiovascular diseases)
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Clinical health not elsewhere classified
UTAS Author:	Srikanth, VK (Dr Velandai Srikanth)
ID Code:	131350
Year Published:	2018
Web of Science^® Times Cited:	45
Deposited By:	Menzies Institute for Medical Research
Deposited On:	2019-03-14
Last Modified:	2019-04-08
Downloads:	0

Repository Staff Only: item control page